downgrad peer perform
report limit sole use client wolf research pleas refer disclosur section locat end report analyst
certif disclosur import disclosur pleas go www wolferesearch com/disclosur write us wolf research llc
cro takeaway follow downgrad peer perform
unknown reflect takeaway earn feel better near-term disrupt
given lower-than-fear decrement margin expect rel success shift site monitor
altern good news behind us believ import acknowledg path toward normal
clinic trial site access patient recruit remain highli uncertain potenti vulner second wave
outbreak offici wait see mode estim across group move significantli higher
better margin estim gener unchang discuss downgrad peer
perform outperform stock perform feel increasingli disconnect compani exposur smaller
less financi robust biopharma custom rel peer top pick group remain
cro estim ebitda estim move significantli higher compani primarili due lower
decrement margin vs previou assumpt estim rel unchang remain msd
consensu ebitda compani
cro target price increas target ev ebitda multipl compani move sinc
last updat addit reflect increas confid margin rebound follow strong
result guidanc addit reflect stronger expect book margin outlook
downgrad peer perform lower forward estim modestli reflect slower revenu
growth still solidli peer compani potenti face difficult path normal cro
given medp focu smaller biopharma custom revis estim year-end target price move
despit modestli higher target multipl discuss target price repres
ebitda ep price-to-earnings in-lin averag multipl premium
averag multipl think current valuat reason balanc current risk medp strong balanc
sheet track record above-market organ growth upsid target price see better risk reward
elsewher downgrad peer perform outperform note ytd outperform
outperform ex
compani data factset wolf research llc
note total return reflect annual dividend yield compar year-end price target
compani data factset wolf research llc
rel price return xlv
compani data factset wolf research llc
takeaway result commentari
pictur takeaway result commentari
overal updat better estim
revenue guidanc modestli better iclr much better
decrement margin significantli lower initi assumpt
book impact custom decision-mak slow end
lh saw biggest step-down net book-to-bil vs recent trend
book net book-to-bil quit strong despit disrupt
compani expect gradual improv access trial site
trial extend gener increment cost thu revenu
trial recruit harder catch-up shift right dynam
like impact larg pharma due financi resourc
extend trial burdensom
may need repriorit clinic program conserv cash
impact on-going trial larg expect continu
trial start impact sponsor gener seem take wait
compani data factset wolf research llc
note shown metric avail show impli quarterli calcul lh
compani data wolf research llc
compani data wolf research llc
cro guidanc updat full-year
revis y/i revenu growth report organ
revis ep y/i
revenu lsd-to-msd report msd organ
ep y/i q/q
withdrew guidanc provid outlook
revenu guid y/i q/q
ep guid y/i q/q
impli ebit margin y/i q/q
revis revenu guid y/i
revis ebitda y/i impli margin y/i
revis ep y/i vs origin guidanc
revenue ebitda margin y/i
expect revenu profit
revenu y/i q/q ebitda y/i
 q/q impli ebitda margin midpoint y/i q/q
withdrew guidanc provid outlook
revenu y/i q/q
ep y/i q/q
impli ebit margin y/i q/q
expect ebitda margin cost manag strategi
y/i vs estim
compani data factset wolf research llc
prah revenu guidanc much better would expect base guidanc iclr
analyz revenu guidanc estim impli guidanc clinic servic revenu
assum data solut revenu remain flat q/q y/i use compani guidanc clinic pass
through call clinic servic revenu
analysi impli clinic servic revenu expect y/i less declin headlin revenu
note larger-than-averag exposur compar peer expect resili
current environ full-servic work
relat pass-through certainli pass-through revenu slightli higher anticip come
quarter in-lin percentag saw brought number
obvious travel includ number anticip obvious stay-at-hom order place
right travel quarter look sequenti expect come good chunk
versu last year anticip somewher say servic revenu
compani data wolf research llc
midpointtot solut clinic segment servic servic downgrad peer perform outperform
downgrad peer perform outperform
downgrad
stock perform feel increasingli disconnect medp exposur
smaller less financi robust biopharma custom rel peer
current valuat reason balanc current risk medp strong
balanc sheet track record above-market organ growth
exposur
gener revenu small biopharma
like impact delay disrupt larg
pharma due financi resourc
extend trial burdensom may need repriorit clinic program
expect end start term employe although
recogn reduct focus non-bil staff
similar comment made expect
gener above-averag organ growth leav us somewhat concern
lower forward estim modestli reflect slower revenu
growth still solidli peer
estim gener line w/ consensu vs msd ebitda
upsid rest group
revis estim year-end target price move
target price repres ebitda ep
price-to-earnings in-lin averag multipl premium
averag multipl
compani data factset wolf research llc
commentari disrupt earn
august troendl chairman presid ceo earn long-term basi
busi revenu impact reluct sponsor initi new trial award new
busi uncertain environ cost may higher due extend timelin
alreadi appar new busi award reduc futur revenu delay trial start
cancel reduc new busi award partial off-set addit revenu
extens on-going trial discuss recruit delay recruit slow
say
howev elong timelin studi recruit slow recruit
slow may challeng smaller client abil financi support expens delay
major client small mani cash balanc sheet complet
trial without rais addit fund due challeng face pandem
expect revenu profit year full-year howev
extent drop reason estim time reason withdraw
rather updat previou guidanc
compani data wolf research llc
commentari staf level earn
analyst see guy brought new employe quarter look like goe
quarter great manag kind think hire
cours year
august troendl chairman presid ceo earn expect staff number
probabl flat year reduct mention staff past
month expect end year enter year term staff number
august troendl chairman presid ceo earn okay ye overal action
repres close staff heavili weight toward admin function
includ billabl staff et cetera know go year expect
least growth revenu shoot even
prepar caught hire need get well ahead
growth expect growth year readdress
think plenti staff place thing turn around abl grow rapidli
compani data wolf research llc
quarterli headcount revenu growth
compani data wolf research llc
commentari cancel mix rfp earn
august troendl chairman presid ceo earn sever five cancel
relat covid alway take cancel identifi multipl reason much cancel
exclus someth go great oh covid go make us decid cancel studi
kind project might strongest opportun whatev reason
covid would progress seen cancel surpris other
jess geiger coo-laboratori oper cfo earn guess littl perspect mayb give
portfolio composit backlog small biotech consist backlog mix
consist revenu small biotech backlog compani partner product
larg pharma categori small biotech fund sourc market also partial fund
partnership larg pharma
anoth way look public versu privat compani larg mid-siz compani backlog
public compani small biotech backlog approxim public compani
privat fund compani know give insight cash balanc sheet provid mayb
littl bit insight composit fund sourc current state
august troendl chairman presid ceo earn overal rfp flow flat
mean pretti darn good thing good
think seen see lot pretti well-fund good opportun held view greater cost
uncertainti around run trial today rather hope three month six month
think demand look pretti good pretti consist last year
compani data wolf research llc
expect end start year term employe
taken liter would suggest initi guidanc might reason way think estim
howev recogn reduct focus non-bil staff feel appropri staf
place grow quickli environ normal
staf action similar made expect gener above-averag
organ growth leav us somewhat concern
compani data wolf research llc
larg pharma commentari clinic trial disrupt
larg pharma say clinic trial disrupt
delay on-sit start-up activ continu one run remot
new clinic trial
paus screen new patient recruit start reactiv
expect limit impact clinic trial fulli enrol
amend on-going clinic trial ensur safeti
expect much impact late-stag clinic trial
anticip delay earli clinic trial due complex safeti concern
slow recruit clinic trial
paus recruit pivot program
studi gsk estim delay
support new enrol on-going studi priorit safeti
paus new clinic trial start enrol on-going program
expect chang on-going late-stag studi except previous
adjust clinic trial ensur safeti minim stress health care system
plan clinic trial resum year-end local restrict lift
fulli recruit trial lower risk delay
compani data factset wolf research llc
larg pharma say clinic trial disrupt
virtual oper clinic trial remain schedul
reduc enrol certain jurisdict halt enrol
continu launch new clinic trial across jurisdict
regulatori submiss remain track
impact clinic trial larg manag
see disrupt start-up plan phase slowdown enrol
brief paus clinic trial recruit
key pipelin program continu move forward
pivot readout clinic trial start larg track
on-going clinic studi oncolog seem less impact continu
enrol studi cancer
outsid oncolog new trial enrol difficult
clinic develop team continu start random clinic trial keep
patient studi pipelin molecul concern
studi abil recruit new patient slow
except track deliv program featur capit market
compani data factset wolf research llc
discuss ventur capitalist bruce booth excel blog post biopharma ventur capit fund strong
compani data life vc factset wolf research llc
biopharma ventur capit fund also quit durabl financi crisi particularli relat ventur capit
fund sector
compani data life vc factset wolf research llc
summari estim chang
summari estim chang
compani data factset wolf research llc
compani data factset wolf research llc
revenu gone
consensu revenu cro group decreas sinc
interestingli consensu revenu also decreas
shown consensu estim shift right full year appear give credit
compani catch delay work move
consensu also appear give much credit increment revenu gener delay on-going trial
consensu revenu iclr
compani data factset wolf research llc
estim estim chang comparison vs consensu
compani data factset wolf research llc
vs vs vs iclr estim estim chang comparison vs consensu
compani data factset wolf research llc
vs vs vs estim estim chang comparison vs consensu
compani data factset wolf research llc
vs vs vs estim estim chang comparison vs consensu
note comparison vs consensu impact inclus analyst treatment amort expens
compani data factset wolf research llc
vs vs vs estim estim chang comparison vs consensu
note consensu ep guidanc rang due previou estim outlier estim outsid guidanc rang
compani data factset wolf research llc
vs vs vs estim estim chang comparison vs consensu
compani data factset wolf research llc
revenu model
model impact cro group proven quit challeng given interplay exist
clinic trial new clinic trial potenti catching-up revenu abl recogn due
model establish baselin revenu contribut exist vs new trial next month allow
user make discret assumpt blend back togeth calcul potenti impact overal
show illustr break-out monthli revenu impact subsequ month
becom increasingli depend clinic trial start yet occur end
approxim cro monthli revenu mix januari decemb
compani report wolf research llc
start start revenu model drive individu compani model estim
revenu model appli adjust previous forecast revenu earn estim compani
consolid cro model singl file chang made industri model flow
compani consist basi
revenu revis non-cro segment less sever
compani report wolf research llc
revenu model clinic trial progress
on-going clinic trial work stream abl continu thu gener revenu given complet revenu
recognit other relat trial site heavili impact partli replac solut
remot monitor risk-bas monitor
model allow user input much month revenu forecast recogn vs defer vs lost
user also make assumpt pace catch-up defer revenu
oper environ return someth close approxim normal revenu could potenti rise
initi forecast catch-up revenu recogn
model input clinic trial progress
note cro company-specif assumpt better reflect custom servic mix exampl illustr
compani data factset wolf research llc
on-tim on-tim start revenuedef revenueadjust revenu model clinic trial progress
model suggest revenu trial progress come slightli initi forecast catch-
revenu recogn
clinic trial progress revenu vs pre-covid baselin
clinic trial progress revenu vs pre-covid baselin
note cro company-specif assumpt better reflect custom servic mix exampl illustr
compani data factset wolf research llc
next month model assum essenti new clinic trial start
assum work defer rather lost trial start gradual caught
note lack new clinic trial start would disproportion larg impact revenu essenti
work stream would paus anticip revenu recogn vs partial recognit exist trial
model input new clinic trial
note cro company-specif assumpt better reflect custom servic mix exampl illustr
compani data factset wolf research llc
revenu trial on-tim on-tim revenu trial start assumptionstri startsdef startsadjustedadjust revenu model new clinic trial
use model output clinic trial start time assum revenu recogn evenli month
seen assum clinic trial start march april may gradual ramp back start
catch delay trial start
revenu model new trial reflect slow activ march septemb
note cro company-specif assumpt better reflect custom servic mix exampl illustr
compani data factset wolf research llc
unlik work exist trial would expect see revenu exceed pre-covid forecast best scenario
like get caught trial start revenu recognit sometim
model suggest revenu trial start pre-covid baselin
note cro company-specif assumpt better reflect custom servic mix exampl illustr
compani data factset wolf research llc
show model output clinic trial progress new clinic trial
also show blend impact overal revenu time progress weight new clinic trial increas
think like benefit revenu exist trial initi would recogn
leav revenu previou baselin
note cro company-specif assumpt better reflect custom servic mix exampl illustr
compani data factset wolf research llc
trial progressnew clinic trialscombin impact
